Risk of Idiopathic Pneumonia Syndrome After High-Dose Chemotherapy for Hodgkin's Disease
Author Information
Author(s): C Rubio, ME Hill, S Milan, MER O'Brien, D Cunningham
Primary Institution: The Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
What are the risk factors for developing idiopathic pneumonia syndrome (IPS) in patients with Hodgkin's disease undergoing high-dose chemotherapy?
Conclusion
The main avoidable risk factor for fatal IPS after high-dose chemotherapy is the dose of BCNU, particularly for women.
Supporting Evidence
- 28% of patients developed idiopathic pneumonia syndrome (IPS) within a year of high-dose chemotherapy.
- Women receiving more than 475 mg m-2 of BCNU had a significantly higher risk of death from IPS.
- Previous lung disease did not increase the incidence of IPS or risk of a fatal outcome.
Takeaway
This study found that women and higher doses of a specific chemotherapy drug increase the risk of a serious lung problem after treatment for Hodgkin's disease.
Methodology
The study analyzed data from patients treated with BCNU-containing high-dose chemotherapy and hematopoietic support, assessing patient characteristics, treatment details, and outcomes.
Potential Biases
Potential bias due to the retrospective nature of the study and reliance on existing medical records.
Limitations
The study only included patients treated at one institution and may not be generalizable to all settings.
Participant Demographics
60 men and 34 women, median age 29 years (range 15-51 years).
Statistical Information
P-Value
0.001 for BCNU dose and female sex as risk factors.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website